Comment on Ye et al ‘Presence of respiratory failure of COVID-19 infection in rheumatism patients in Wuhan, China’
Comment on Ye et al ‘Presence of respiratory failure of COVID-19 infection in rheumatism patients in Wuhan, China’
复制标题
对 Ye 等人“中国武汉风湿病患者出现 COVID-19 感染呼吸衰竭”的评论
DOI：
10.1136/annrheumdis-2020-218451
复制
发表时间：
2020-07
期刊：
影响因子：
--
通讯作者：
James Cheng Chung Wei
中科院分区：
文献类型：
--
作者：
Xiao-Huan Chen;Chih-Jung Yeh;Han-You Mo;James Cheng Chung Wei
我们饶有兴趣地阅读了 Ye 等人的文章1，该文章报道了风湿性疾病患者中 COVID-19 的临床特征，最值得注意的是，感染了 COVID-19 的风湿性疾病患者比没有风湿性疾病的患者更容易发生呼吸衰竭（38% vs 10%，p<0.001）。作者收集了2020年1月13日至3月15日期间总共2326例COVID-19患者的数据，其中包括21例合并风湿性疾病的患者，并对他们的实验室指标进行了回顾性病例系列研究。然而，研究中的一些结论和发现还需要进一步澄清。
首先，感染 COVID-19 的风湿性疾病患者的样本量只有 21 人，太小，无法以统计可信度推断结果。风湿性疾病通常会影响肺部，这可能会对……造成进一步的损害。
We read with great interest the article by Ye et al ,1 which reported the clinical features of COVID-19 in patients with rheumatic diseases, most notably that respiratory failure developed more commonly in patients with rheumatic disease infected with COVID-19 than those without rheumatic disease (38% vs 10%, p<0.001). The authors collected data from a total of 2326 patients with COVID-19 from 13 January to 15 March 2020, including 21 cases in combination with rheumatic disease, and conducted a retrospective case series study of their laboratory indices. However, some conclusions and findings in the study need to be further clarified.
First, the sample size of patients with rheumatic disease infected with COVID-19 was only 21—too small to extrapolate results with statistical confidence. Rheumatic diseases often affect the lungs, which can cause further damage to …
影响因子：
27.4
作者：
Ye, Cong;Cai, Shaozhe;Dong, Lingli
通讯作者：
Dong, Lingli
影响因子：
13.8
作者：
Borba, Mayla Gabriela Silva;Val, Fernando Fonseca Almeida;Lacerda, Marcus Vinicius Guimaraes
通讯作者：
Lacerda, Marcus Vinicius Guimaraes
影响因子：
5
作者：
Sharmeen, Saika;Elghawy, Ahmed;Yao, Qingping
通讯作者：
Yao, Qingping